Lyora Therapeutics, a biotech startup, has launched with $2.5 million in seed funding to develop genetic medicines targeting inherited retinal diseases that currently lack treatments. Their lead programs, LYA-101 and LYA-102, aim to treat retinitis pigmentosa and Usher Syndrome Type 2 using gene augmentation and CRISPR technology, respectively. The company plans to submit an IND for LYA-101 within 18 months and advance LYA-102 shortly after. Led by CEO Pam Stetkiewicz and a team of experienced experts, Lyora aims to deliver durable, one-time therapies that address the root causes of vision loss.
The global electric vehicle (EV) market is projected to grow annually by 9.0%, reaching a value of $2.74 trillion in 2026, driven by regulatory changes, expanded charging infrastructure, and battery supply-chain development. Key growth areas include ...
Revenium has successfully completed a SOC 2 Type II audit conducted by AuditOne LLP, confirming the security, availability, and confidentiality controls of its AI cost and spend management platform. This certification is crucial as enterprises increa...
Flex secured $70 million in a Series B1 funding round led by Halo Fund to accelerate the launch of Flex Global, an AI-native private banking platform serving high-net-worth business owners in over 100 countries. The platform integrates multi-currency...
Fanatics Studios and DICK’S Sporting Goods’ Cookie Jar & a Dream Studios are producing a documentary about Olympic gymnast Suni Lee. The film offers an intimate look at her life, focusing on her comeback after battling chronic kidney disease and comp...
Rackspace Technology has been recognized as a leader in the 2026 ISG Provider Lens report in the US and UK for managed services in AI-enabled infrastructure and managed cloud hosting with resilient infrastructure. This highlights Rackspace's role as ...
